A recombinant canine parvovirus pseudovirus

By constructing core plasmids and auxiliary plasmids that lack the coding region of the capsid protein, expressing CPV-2 capsid protein and replacing the VP2 coding sequence, the problem of low assembly efficiency of canine parvovirus recombinant pseudovirus system in vitro is solved, and efficient expression and Assembly provides effective tools for genetic engineering research.

CN116376981BInactive Publication Date: 2024-11-01NORTHWEST A & F UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310435495.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-21
Publication Date
2024-11-01
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to stably and efficiently assemble the recombinant pseudovirus system of canine parvovirus (CPV-2) in vitro. It is limited by the virus genome structure and expression regulation mechanism, making it difficult to achieve efficient expression and assembly.

Method used

The core plasmid and helper plasmid that lack the coding region of the capsid protein were constructed, and the CPV-2 capsid proteins VP1 and VP2 were expressed, and the VP2 coding sequence was replaced by exogenous genes such as EGFP fluorescent reporter genes were used to form recombinant plasmids and helper plasmids, and co-transfection was performed. Cells are used to achieve efficient assembly.

Benefits of technology

Overcoming the limitations of viral genomic structure on expression efficiency and assembly efficiency, achieving efficient expression and stable assembly of CPV-2 recombinant pseudoviruses, providing an effective tool for genetic engineering research and vaccine development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116376981B_ABST
    Figure CN116376981B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of viral genetic engineering, and specifically relates to a recombinant canine parvovirus pseudovirus. The present invention constructs a recombinant CPV-2 pseudovirus system expressing exogenous genes by transforming a CPV-2 full-length infectious clone plasmid into a replication-defective recombinant plasmid carrying an exogenous gene. The recombinant CPV-2 pseudovirus system constructed by the present invention can successfully infect F81 cells and effectively express the exogenous genes carried. The problem that the expression efficiency and assembly efficiency are limited when the existing CPV-2 expresses exogenous genes is overcome. This not only provides a good research tool for the study of viral pathogenic mechanisms, but also lays a theoretical foundation for the research and development of genetically engineered multi-unit vaccines and new targeted drugs based on the CPV-2 pseudovirus system, and has broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of virus gene engineering, and in particular relates to a recombinant canine parvovirus pseudovirus. Background Art

[0002] Canine parvovirus type 2 (CPV-2) belongs to the Parvoviridae family and the Parvovirus genus. It is a single-stranded, negative-strand, non-enveloped DNA virus. The diameter of the viral capsid of CPV-2 is about 20nm, with an icosahedral symmetric structure, encapsulating a single-stranded DNA genome of about 5kb. The CPV-2 genome mainly contains two open reading frames (ORFs), ORF1 and ORF2. ORF1 encodes non-structural proteins NS1 and NS2, and ORF2 encodes capsid proteins VP1 and VP2.

[0003] Relying on the reverse genetics operating system, the virus can be manipulated at the molecular level, and the virus genome can be modified and viral vectors can be developed. However, not only is the genome capacity of parvovirus small, but the genome genes are highly overlapping, which limits the construction of recombinant viruses directly based on CPV-2 infectious clones, and it is impossible to develop and apply CPV-2 vectors by directly carrying or expressing exogenous sequences.

[0004] Pseudovirus refers to virus particles assembled from defective nucleic acid molecules wrapped by viral capsid proteins. It has only one cell infection cycle and has high biosafety. It also has the natural structure of the viral capsid surface, is easy to prepare in vitro and has good stability. Currently, pseudovirus systems have been widely used in various fields such as virus host cell screening, antiviral drug screening, new vaccine development, neutralizing antigen epitope research and gene targeted therapy.

[0005] The CPV-2 packaging system in previous studies included a target gene expression plasmid that retained the ITR sequences at both ends and an auxiliary plasmid that provided non-structural and structural proteins required for viral replication. However, the expression efficiency of the auxiliary plasmid containing the full-length sequence of the CPV-2 coding region is limited by the structure of the viral genome itself and depends on the expression regulation mechanism of the viral genome itself, making it difficult to achieve stability in the expansion of production of the recombinant system.

[0006] Therefore, in the art, how to develop a CPV-2 recombinant pseudovirus system with effective expression and higher assembly efficiency, so as to achieve stable and efficient assembly of CPV-2 recombinant pseudovirus in vitro, is still a problem that needs to be solved urgently. Summary of the invention

[0007] In view of the problems of the prior art, the present invention provides a recombinant canine parvovirus pseudovirus, the purpose of which is to retain the non-structural protein coding sequence of the CPV-2 genome, construct a target gene expression plasmid that only lacks the capsid protein coding region, and construct an auxiliary plasmid that can simultaneously and efficiently express the capsid proteins VP1 and VP2, so as to effectively assemble a CPV-2 recombinant pseudovirus that expresses exogenous genes.

[0008] A core plasmid recombinant precursor, wherein the core plasmid recombinant precursor is a nucleotide sequence as shown in SEQ ID NO.1, or a nucleotide sequence having a similarity with SEQ ID NO.1 of greater than or equal to 90%.

[0009] The present invention also provides a recombinant plasmid, which comprises mutually connected exogenous gene sequences and the core plasmid recombinant precursor described in claim 1.

[0010] Preferably, the exogenous gene sequence is the EGFP fluorescent reporter gene.

[0011] The invention also provides a recombinant canine parvovirus pseudovirus, which comprises the recombinant plasmid and an auxiliary plasmid for expressing CPV-2 capsid protein.

[0012] Preferably, the auxiliary plasmid for expressing CPV-2 capsid protein comprises a plasmid vector, a V1 segment, a V2 segment, a T2A segment and a V3 segment connected in series in sequence;

[0013] Wherein, the V1 fragment is a nucleotide sequence as shown in SEQ ID NO.2, or a nucleotide sequence having a similarity with SEQ ID NO.2 of greater than or equal to 90%;

[0014] The V2 fragment is a nucleotide sequence as shown in SEQ ID NO.3, or a nucleotide sequence having a similarity of greater than or equal to 90% to SEQ ID NO.3;

[0015] The T2A is a nucleotide sequence as shown in SEQ ID NO.4, or a nucleotide sequence having a similarity of greater than or equal to 90% to SEQ ID NO.4;

[0016] The V3 fragment is a nucleotide sequence as shown in SEQ ID NO.5, or a nucleotide sequence having a similarity with SEQ ID NO.5 of greater than or equal to 90%.

[0017] Preferably, the plasmid vector is selected from pCDNA3.1.

[0018] Preferably, the recombinant canine parvovirus pseudovirus is prepared according to the following method: the recombinant plasmid and the auxiliary plasmid for expressing CPV-2 capsid protein are transfected into cells, and the virus liquid is isolated after continued cultivation.

[0019] The present invention also provides a method for preparing the above-mentioned recombinant canine parvovirus pseudovirus, comprising the following steps:

[0020] Step 1, using CPV-2 genomic DNA as a template, amplifying the V1 segment, V2 segment and V3 segment, splicing the V1 segment and the V2 segment, and introducing T2A to connect the V2 segment and the V3 segment to obtain a segment VP2-T2A-VP1 containing an expression cassette transcription region; the VP2-T2A-VP1 comprises a V1 segment, a V2 segment, a T2A segment and a V3 segment connected in series in sequence;

[0021] Step 2, connecting VP2-T2A-VP1 with a plasmid vector to obtain a helper plasmid for expressing CPV-2 capsid protein;

[0022] Step 3, using the CPV-2 full-length infectious clone plasmid as a template, amplifying the core plasmid recombinant precursor, and connecting the core plasmid recombinant precursor with the exogenous gene sequence to obtain a recombinant plasmid;

[0023] Step 4, transfecting the recombinant plasmid and the auxiliary plasmid for expressing CPV-2 capsid protein into cells, and separating the virus liquid after continuing to culture.

[0024] Preferably, in step 1, the amplification primers include:

[0025] The upstream primer used to amplify the V1 fragment has a nucleotide sequence as shown in SEQ ID NO.7.

[0026] The downstream primer used to amplify the V1 fragment has a nucleotide sequence as shown in SEQ ID NO.8.

[0027] The upstream primer used to amplify the V2 fragment has a nucleotide sequence as shown in SEQ ID NO.9.

[0028] The downstream primer used to amplify the V2 fragment has a nucleotide sequence as shown in SEQ ID NO.10.

[0029] The upstream primer used to amplify the V3 fragment has a nucleotide sequence as shown in SEQ ID NO.11.

[0030] The downstream primer used to amplify the V3 fragment has a nucleotide sequence as shown in SEQ ID NO.12;

[0031] And / or, in step 2, VP2-T2A-VP1 and the plasmid vector are both ligated after being double-digested with BamH I / Xba I;

[0032] And / or, in step 3, the amplification primers include:

[0033] The upstream primer used to amplify the core plasmid recombinant precursor has a nucleotide sequence as shown in SEQ ID NO.15.

[0034] The downstream primer used to amplify the core plasmid recombinant precursor has a nucleotide sequence as shown in SEQ ID NO.16;

[0035] The core plasmid recombinant precursor and the exogenous gene sequence are connected by the ClonExpress II One Step Cloning Kit method;

[0036] And / or, in step 4, the cells are F81 cells.

[0037] The present invention also provides use of the recombinant canine parvovirus pseudovirus for expressing foreign genes.

[0038] The present invention constructs a core plasmid recombinant precursor CPV (ΔVP2) lacking the VP2 coding sequence, which retains the inverted terminal repeat sequences at both ends of the CPV-2 genome and the full-length sequence of NS1. Further, by replacing the VP2 coding sequence with an exogenous gene sequence (such as a fluorescent reporter gene EGFP sequence), a recombinant plasmid expressing an exogenous gene can be constructed.

[0039] Furthermore, the present invention also constructs an auxiliary plasmid pVP2-T2A-VP1 that can effectively express CPV-2 capsid proteins VP1 and VP2 simultaneously, providing VP1 and VP2 proteins for virus assembly for pseudovirus packaging.

[0040] The above recombinant plasmid and the auxiliary plasmid pVP2-T2A-VP1 are co-transfected into cells to package a CPV recombinant pseudovirus that has infection ability and can effectively express foreign genes.

[0041] The invention overcomes the limitation of the viral genome structure on the expression efficiency and assembly efficiency when the existing CPV-2 expresses foreign genes, and has a good application prospect.

[0042] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0043] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1It is a schematic diagram of the process of constructing recombinant canine parvovirus pseudovirus.

[0045] Figure 2 This is a schematic diagram of the construction of the auxiliary plasmid pVP2-T2A-VP1.

[0046] Figure 3 This is the result of western blotting detection of VP1 and VP2 expression after F81 cells were transfected with the auxiliary plasmid pVP2-T2A-VP1.

[0047] Figure 4 This is a schematic diagram of the construction of the core plasmid pCPV-EGFP.

[0048] Figure 5 This is the expression of EGFP fluorescent reporter gene after F81 cells were transfected with core plasmid pCPV-EGFP.

[0049] Figure 6 This is the result of western blotting detection of EGFP expression in F81 cells after core plasmid pCPV-EGFP was transfected.

[0050] Figure 7 It is the detection result of the viral copy number of the CPV-2 recombinant pseudovirus.

[0051] Figure 8 This is the expression of EGFP fluorescent reporter gene after F81 cells were infected with CPV-2 recombinant pseudovirus. DETAILED DESCRIPTION

[0052] In the following examples, reagents and raw materials not specifically described are all commercially available.

[0053] Example 1 Recombinant canine parvovirus pseudovirus

[0054] The construction process of the recombinant canine parvovirus pseudovirus in this example is as follows Figure 1 As shown, the recombinant canine parvovirus pseudovirus includes a recombinant plasmid and a helper plasmid for expressing CPV-2 capsid protein.

[0055] The recombinant plasmid (hereinafter referred to as core plasmid pCPV-EGFP) includes an interconnected exogenous gene sequence (in this embodiment, the exogenous gene sequence is the EGFP fluorescent reporter gene) and a core plasmid recombinant precursor (hereinafter abbreviated as CPV (ΔVP2)).

[0056] The auxiliary plasmid used to express CPV-2 capsid protein is a plasmid vector (in this example, the plasmid vector is selected from plasmid pCDNA3.1) into which the V1 fragment, V2 fragment, T2A and V3 fragment connected in series are inserted.

[0057] The nucleotide sequences of the above fragments are as follows:

[0058] CPV (ΔVP2) sequence (SEQ ID NO.1):

[0059]

[0060] CTTAAAGACAGATTGATACTAAGAGACGGAGTCACTGCCAACCGAGAC

[0061] GGTCATAGCTGTTTCCTGTGTGCCGCTTCCTCGCTCACTGACTCGCTGC

[0062] GCTCGGTCGTTACTGACCATTTAAATCATACCTGACCTCCATAGCAGAA

[0063] AGTCAAAAGCCTCCGACCGGAGGCTTTTGACTTGATCGGCACGTAAGA

[0064] GGTTCCAACTTTCACCATAATGAAATAAGATCACTACCGGGCGTATTTTT

[0065] TGAGTTATCGAGATTTTCAGGAGCTAAGGAAGCTAAAATGAGCCATATT

[0066] CAACGGGAAACGTCTTGCTCTAGGCCGCGATTAAATTCCAACATGGATG

[0067] CTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGT

[0068] GCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTC

[0069] TGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGG

[0070] TCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCA

[0071] TTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACAGCGATCCCCG

[0072] GGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAA

[0073] TATTGTTGATGCGCTGGCCGTGTTCCTGCGCCGGTTGCATTCGATTCCTG

[0074] TTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGACTCGCTCAGGCG

[0075] CAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACG

[0076] AGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAAC

[0077] TTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTT

[0078] GATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGG

[0079] ACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAAC

[0080] TGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAAT

[0081] ATGGTATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCG

[0082] ATGAGTTTTTCTAAGTGACCAAACAGGAAAAAACCGCCCTTAACATGG

[0083] CCCGCTTTATCAGAAGCCAGACATTAACGCTTCTGGAGAAACTCAACG

[0084] AGCTGGACGCGGATGAACAGGCAGACATCTGTGAATCGCTTCACGACC

[0085] ACGCTGATGAGCTTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGG

[0086] TGAAAACCTCTGATGAGGGCCCAAATGTAATCACCTGGCTCACCTTCGG

[0087] GTGGGCCTTTCTGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTG

[0088] ACGAGCATCACAAAAATCGATGCTCAAGTCAGAGGTGGCGAAACCCGA

[0089] CAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCG

[0090] CTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCC

[0091] CTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAG

[0092] TTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCC

[0093] CGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCC

[0094] AACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC

[0095] AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG

[0096] TGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCG

[0097] CTCTGCTGAAGCCAGTTACCTCGGAAAAAGAGTTGGTAGCTCTTGATC

[0098] CGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCA

[0099] GCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATTTT

[0100] CTACCGAAGAAAGGCCCACCCGTGAAGGTGAGCCAGTGAGTTGATTGC

[0101] AGTCCAGTTACGCTGGAGTCAATAGGCGTATCACGAGGCCCTTTCGTTG

[0102] TAAAACGACGGCCAGTCGAACCACGCAATGCGTCTCGATCCGCAGTGT

[0103] CTTGCGTCTCTATTCTTTAGAACCAACTGACCAAGTTCACGTACGTATG

[0104] ACGTGATGACGCGCGCTGCGCGCGCTTCCTACGGCAGTCACACGTCAT

[0105] ACGTACGCTCCTTGGTCAGTTGGTTCTAAAGAATGATAGGCGGTTTGTG

[0106] TGTTTAAACTTGGGCGGGAAAAGGTGGCGGGCTAATTGTGGGCGTGGT

[0107] TAAAGGTATAAAAGACAAACCATAGACCGTTACTGACATTCGCTTCTTG

[0108] TCTTTGACAGAGTGAACCTCTCTTACTTTGACTAACCATGTCTGGCAAC

[0109] CAGTATACTGAGGAAGTTATGGAGGGAGTAAATTGGTTGAAGAAACAT

[0110] GCAGAAAATGAAGCATTTTCGTTTGTTTTTAAATGTGACAACGTCCAAC

[0111] TAAATGGAAAGGATGTTCGCTGGAACAACTATACCAAACCAATTCAAAA

[0112] TGAAGAGCTAACATCTTTAGTTAGAGGAGCACAAACAGCAATGGATCA

[0113] AACCGAAGAAGAAGAAATGGACTGGGAATCGGAAGTTGATAGTCTCGC

[0114] CAAAAAGCAAGTACAAACTTTTGATGCATTAATTAAAAAATGTCTTTTT

[0115] GAAGTCTTTGTTTCTAAAAATATAGAACCAAATGAATGTGTTTGGTTTTAT

[0116] TCAACATGAATGGGGAAAAGATCAAGGCTGGCATTGTCATGTTTTACTT

[0117] CATAGTAAAAACTTACAACAAGCAACTGGTAAATGGCTACGCAGACAA

[0118] ATGAATATGTATTGGAGTAGATGGTTGGTGACTCTTTGTTCGGTAAACTT

[0119] AACACCAACTGAAAAGATTAAGCTCAGAGAAATTGCAGAAGATAGTGA

[0120] ATGGGTGACTATATTAACATACAGACATAAGCAAACAAAAAGACTAT

[0121] GTTAAAATGGTTCATTTTGGAAATATGATAGCATATTACTTTTTAACAAA

[0122] GAAAAAAATTGTCCACATGACAAAAGAAAGTGGCTATTTTTTAAGTACT

[0123] GATTCTGGTTGGAAATTTAACTTTATGAAATATCAAGACAGACAAAATTG

[0124] TCAGCACACTTTACACTGAACAAATGAAACCAGAAACCGTTGAAACCA

[0125] CAGTGACGACAGCACAGGAAACAAAGCGCGGGGAGAATTCAAACTAAA

[0126] AAGGAAGTGTCAATCAAATGTACTTTGCGGGACTTGGTTAGTAAAAGA

[0127] GTAACATCACCTGGAGACTGGATGATGTTACAACCAGATAGTTTATTTG

[0128] AAATGATGGCGCAACCAGGAGGTGAAATCTTTTAAAAAATACACTTG

[0129] AAATTTGACTTTGACTTTAGCAAAAAAAAACAGCATTTGAATTAAT

[0130] ACTTGAAAAAGCAGATAATACTAAGCTAACTACTTTGATCTTGCAAAT

[0131] TCTAGAACATGTCAAATTTTTAGAATGCACGGATGGAATTGGATTAAAG

[0132] TTTGTCACGCTATAGCATGTGTTTTAAATAGCAAGGTGGTAAAAGAAA

[0133] TACAGTTCTTTTTCATGGACCAGCAATCAGGAAAATCTATCATTGCT

[0134] CAAGCCATAGCACAAGCTGTGGGTAATGTTGGTTGTTATAATGCAGCAA

[0135] ATGTAAATTTTCCATTTAATGACTGTACCAATAAAAAATTTAATTTGGATTG

[0136] AAGAAGCTGGTAACTTTGGTCAACAAGTTAATCAATTTAAAGCAATCTG

[0137] TTCTGGACAAACAATTAGAATTGATCAAAAAGGTAAGGAAGTAAAGCA

[0138] AATTGAACCAACTCCAGTAATTATGACAACTAATGAAAATATAACAATT

[0139] GTGAGAATTGGATGTGAAGAAAGACCTGAACATACACAACCAATAAGA

[0140] GACAGAATGCTGAACATTAAGTTAGTGTGTAAGCTTCCAGGAGACTTTG

[0141] GTTTGGTTGATAAAGAGGAATGGCCTTTAATATGTGCATGGTTAGTTAAG

[0142] CATGGTTTTGTATCAACCATGGCTAACTATACACATCACTGGGGAAAAG

[0143] TACCAGAATGGGATGAAAACTGGGCGGAGCCTAAAATACAAGAAGGTA

[0144] TAAATTCACCAGGTTGCAAAGACTTAGAGACACAAGCGGCAAGCAATC

[0145] CTCAGAGTCAAGACCAAGTTCTAACTCCTCTGACTCCGGACGTAGTGG

[0146] ACCTTGCACTGGAACCGTGGAGTACTCCAGATACGCCTATTGCAGAAA

[0147] CTGCAAATCAACAATCAAACCAACCTGGCGTTACTCACAAAGACGTGC

[0148] AAGCGAGTCCAACGTGGTCCGAAATAGAGGCAGACCTGAGAGCCATCT

[0149] TTACTTCTGAACAATTGGAAGAAGATTTTCGAGACGACTTGGATTAAGG

[0150] TACGATGGCACCTCCGGCAAAGAGAGCCAGGAGAGGTAAGGGTGTGTT

[0151] AGTGAAGTGGGGGGAGGGGAAAGATTTAATAACTTAACTAAGTATGTAT

[0152] TTTTTTGTAGGACTTGTGCCTCCAGGTTATAAATATCTTGGGCCTGGGAA

[0153] CAGTCTTGACCAAGGAGAACCAACTAACCCTTCTGACGCCGCTGCAAA

[0154] AGAACACGACGAAGCTTACGCTGCTTATCTTCGCTCTGGTAAAAACCCA

[0155] TACTTATATTTCTCGCCAGCAGATCAACGCTTTATAGATCAAACTAAGGA

[0156] CGCTAAAGATTGGGGGGGGAAAATAGGACATTATTTTTTTAGCGCTAAA

[0157] AAGGCAATTGCTCCAGTATTAACTGATACCCCAGATCATCCATCAACATC

[0158] AAGACCATCAAAACCAACTAAAAGAAGTAAACCACCACCTCATATTTT

[0159] CATCAATCTTGCAAAAAAAAAAAAAACCGGTGCAGGACAAGTAAAAAGAGACAATCTTGCACCAATG;

[0160] V1 fragment (SEQ ID NO.2):

[0161] GCGGATCCGATGAAAACTGGGCGGAGCCTAAAATACAAGAAGGTATAAATTCACCAGGTTGCAAAGACTTAGAGACACAAGCGGCAAGCAATCCTCAGAGTCAAGACCAAGTTCTAACTCCTCTGACTCCGGACGTAGTGGACCTTGCACTGGAACCGTGGAGTACTCCAGATACGCCTATTGCAGAAACTGCAAATCAACAATCAAACCAACCTGGCGTTACTCACAAAGACGTGCAAGCGAGTCCAACGTGGTCCGAAATAGAGGCAGACCTGAGAGCCATCTTTACTTCTGAACAATTGGAAGAAGATTTTCGAGACGACTTGGATT;

[0162] V2 fragment (SEQ ID NO.3):

[0163]

[0164] T2A linker sequence (SEQ ID NO.4):

[0165] GAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAAT CCCGGCCCT;

[0166] Fragment V3 (SEQ ID NO.5):

[0167]

[0168] .

[0169] Example 2 Preparation and Identification of Recombinant Canine Parvovirus Pseudovirus

[0170] This example provides a method for preparing the recombinant canine parvovirus pseudovirus described in Example 1 and the results of its identification experiment. The specific steps are as follows:

[0171] (I) Construction and identification of auxiliary plasmid pVP2-T2A-VP1

[0172] 1.1 Extraction of CPV-2 genomic DNA

[0173] Take 437.5 μL of CPV-2 virus supernatant, add 50 μL of 10% SDS and 12.5 μL of proteinase K, incubate at 55° C. for 30 min, and extract viral DNA, namely CPV-2c genomic DNA (MT892649), according to the phenol-chloroform method.

[0174] 1.2 Cloning of V1, V2 and V3 sequences

[0175] Using the extracted CPV-2c genomic DNA as a template, fragment V1 was amplified using primers VP-F1 / VP-R1; using the extracted CPV-2c genomic DNA as a template, fragment V2 was amplified using primers VP-F2 / VP-R2; using the extracted CPV-2c genomic DNA as a template, fragment V3 was amplified using primers VP-F3 / VP-R3.

[0176] The above amplifications were completed using a PCR instrument. The reaction system was: 5×EVO Buffer 10μL, dNTP Mix (10mM) 1μL, upstream and downstream primers (both 10μM) 2μL each, Phanta EVO Super-Fidelity DNA Polymerase (vazyme) 1μL, template DNA (150ng / μL) 1μL, and ddH2O3 3μL. The reaction procedure was: 95℃ pre-denaturation for 3min; 95℃ denaturation for 15s, 55℃ annealing for 15s, 72℃ extension for 1min, 30 cycles; 72℃ extension for 10min. The PCR amplification products were separated by 1% agarose gel electrophoresis and purified and then recovered the target fragments V1 (330bp), V2 (2224bp) and V3 (2210bp).

[0177] The PCR amplification primers for V1, V2 and V3 are as follows:

[0178] Upstream primer VP-F1 (SEQ ID NO.7):

[0179]

[0180] Downstream primer VP-R1 (SEQ ID NO.8):

[0181]

[0182] Upstream primer VP-F2 (SEQ ID NO.9):

[0183]

[0184] Downstream primer VP-R2 (SEQ ID NO.10):

[0185]

[0186] Upstream primer VP-F3 (SEQ ID NO.11):

[0187]

[0188] Downstream primer VP-R3 (SEQ ID NO.12):

[0189]

[0190] In the above primers, the underlined part is the restriction endonuclease recognition site, and the frame part is the part related to the T2A sequence.

[0191] 1.3 Construction of auxiliary plasmid pVP2-T2A-VP1

[0192] like Figure 2 As shown, the recovered fragments V1 and V2 were used as templates, and VP-F1 / VP-R2 were used as upstream and downstream primers for overlap PCR. The fragment V1-V2 was obtained by amplification according to the above reaction procedure. The recovered fragments V1-V2 and V3 were used as templates, and VP-F1 / VP-R3 were used as upstream and downstream primers for overlap PCR. The fragment V1-V2-T2A-V3 was obtained by amplification according to the above reaction procedure. The gel-purified V1-V2-T2A-V3 was ligated with the pCDNA3.1 plasmid after BamH I / Xba I double restriction digestion. The ligation product was transformed into DH5α competent medium (Invitrogen Company). After overnight culture on the plate, a single colony was picked for colony PCR identification.

[0193] The positive colonies were sent to the company for sequencing and identification. The plasmid with the correct sequencing was named pVP2-T2A-VP1. After the positive bacteria were cultured, the plasmid was extracted and the concentration of the plasmid was measured for later use.

[0194] 1.4 Expression and identification of auxiliary plasmid pVP2-T2A-VP1

[0195] F81 cells (Punosai) were evenly spread on the cell culture plate, cultured at 37°C and 5% CO2, and the cells were transfected when the cell density reached 80%. That is, the auxiliary plasmid pVP2-T2A-VP1 and Lipo8000 transfection reagent (Biyuntian) were diluted with an equal volume of serum-free and dual-antibody-free cell culture medium, and then the Lipo8000 dilution was slowly added to the auxiliary plasmid pVP2-T2A-VP1 dilution, mixed, and the plasmid-transfection reagent mixture was obtained; the original culture medium of F81 cells was discarded, and the cells were washed once with serum-free and dual-antibody-free cell culture medium, and the plasmid-transfection reagent mixture was slowly added to the cell culture plate, and the culture was continued for 6 hours, the transfection incubation solution was discarded, and the complete culture medium was added to continue the culture.

[0196] After culturing for 48 hours after transfection, the cells were collected and centrifuged at 3000 rpm for 5 minutes. The cell pellet was collected and lysed in an ice bath for 30 minutes with an appropriate amount of RIPA lysis buffer (Biyuntian). The supernatant was transferred to a new centrifuge tube and boiled with protein loading buffer for denaturation, and then detected by western blotting.

[0197] The results are as follows Figure 3 As shown, using CPV Capsid (Novus) antibody, the expression of CPV-2c capsid proteins VP1 and VP2 were detected in both the pVP2-T2A-VP1 transfection group and the CPV-2c infected F81 cell positive control group, while no specific bands were detected in the untreated negative control group. The results indicate that the auxiliary plasmid pVP2-T2A-VP1 was successfully constructed and can simultaneously express CPV-2c capsid proteins VP1 and VP2.

[0198] (II) Construction and identification of core plasmid pCPV-EGFP

[0199] 2.1 Construction of pCPV-EGFP

[0200] Using pEGFP-N1 as template, primers EGFP F / EGFP R were used to amplify the EGFP fluorescent reporter gene sequence; using the CPV-2 full-length infectious clone plasmid (preserved in this experiment) as a template, primers CPV F / CPV R were used to amplify CPV (ΔVP2) lacking the VP2 coding sequence. CPV (ΔVP2) retains the inverted terminal repeat sequences at both ends of the CPV-2 genome and the full-length NS1 sequence.

[0201] The above amplifications were completed using a PCR instrument. The reaction system was: 5×EVO Buffer 10μL, dNTP Mix (10mM) 1μL, upstream and downstream primers (both 10μM) 2μL each, Phanta EVO Super-Fidelity DNA Polymerase (vazyme) 1μL, template DNA (150ng / μL) 1μL, and ddH2O3 3μL. The reaction procedure was: 95℃ pre-denaturation for 3min; 95℃ denaturation for 15s, 55℃ annealing for 15s, 72℃ extension for 1min, 30 cycles; 72℃ extension for 10min. The PCR amplification products were separated by 1% agarose gel electrophoresis and the fragments EGFP and CPV (ΔVP2) were purified and recovered.

[0202] The PCR amplification primers for EGFP fluorescent reporter gene and CPV (ΔVP2) are as follows:

[0203] Upstream primer EGFP F (SEQ ID NO.13):

[0204]

[0205] Upstream primer EGFP R (SEQ ID NO.14):

[0206]

[0207] The part without italic bold is the homologous sequence for ligation; the part with italic bold is the EGFP fluorescent reporter gene sequence.

[0208] Upstream primer CPV F (SEQ ID NO.15):

[0209]

[0210] Downstream primer CPV R (SEQ ID NO.16):

[0211]

[0212] like Figure 4 As shown, EGFP and CPV (ΔVP2) were ligated using a ClonExpress II One Step Cloning Kit (37°C for 30 min), and the ligation product was transformed into DH5α competent cells (Invitrogen). After plating, the cells were cultured at 37°C overnight, and single colonies were picked for colony PCR identification.

[0213] The positive colonies were sent to the company for sequencing and identification. The recombinant plasmids with positive sequencing were named pCPV-EGFP. After the positive bacteria were cultured, the plasmids were extracted and the concentration of the plasmids was measured for later use.

[0214] 2.2 Identification of pCPV-EGFP

[0215] The expression of EGFP fluorescent reporter gene was verified by transfecting F81 cells with pCPV-EGFP, as follows:

[0216] Use an equal volume of serum-free and dual-antibody-free cell culture medium to dilute pCPV-EGFP and Lipo8000 transfection reagent (Biyuntian), then slowly add the Lipo8000 dilution to the pCPV-EGFP dilution and mix well to obtain a plasmid-transfection reagent mixture. Discard the original culture medium of F81 cells, wash once with serum-free and dual-antibody-free cell culture medium, slowly add the plasmid-transfection reagent mixture to the cell culture plate, continue to culture for 6 hours, discard the transfection incubation solution, and add complete culture medium to continue culturing.

[0217] After culturing for 24 hours after transfection, the green fluorescence expression of the EGFP fluorescent reporter gene was observed under a fluorescence microscope ( Figure 5 ), the core plasmid pCPV-EGFP can successfully express the exogenous genes it carries.

[0218] After culturing for 48 hours after transfection, the cells were collected and centrifuged at 3000 rpm for 5 minutes. The cell pellet was collected and lysed in an ice bath for 30 minutes with an appropriate amount of RIPA lysis buffer (Biyuntian). The supernatant was transferred to a new centrifuge tube and boiled with protein loading buffer for denaturation, and then detected by western blotting.

[0219] The results are as follows Figure 6 As shown, using EGFP antibody (Cell Signaling Technology), the expression of EGFP was detected in the pCPV-EGFP transfection group, while no specific band was detected in the non-transfected negative control group. The results show that the constructed core plasmid pCPV-EGFP can effectively express the EGFP fluorescent reporter gene it carries.

[0220] (III) Packaging of CPV-2 recombinant pseudovirus carrying EGFP fluorescent reporter gene

[0221] F81 cells were evenly spread on a cell culture plate and cultured at 37°C with 5% CO2. When the cell density reached 80%, cell transfection was started. That is, the two plasmids pCPV-EGFP and pVP2-T2A-VP1 are added to the serum-free and dual antibody-free cell culture medium in sequence, and gently mixed. An equal volume of serum-free and dual antibody-free cell culture medium is taken to dilute the Lipo8000 transfection reagent (Biyuntian), and then the Lipo8000 dilution is slowly added to the double plasmid (pCPV-EGFP and pVP2-T2A-VP1 are mixed in equal proportions) dilution, gently mixed and allowed to stand for 20 minutes to obtain a plasmid-transfection reagent mixture; the original culture medium of F81 cells is discarded, the cells are washed once with serum-free and dual antibody-free culture medium, and the plasmid-transfection reagent mixture is slowly added to the cell culture plate (i.e., the core plasmid pCPV-EGFP and the auxiliary plasmid pVP2-T2A-VP1 are co-transfected into F81 cells at the same time), and the culture is continued for 6 hours, the transfection incubation solution is discarded, the cells are washed twice with serum-free and dual antibody-free culture medium, and complete culture medium is added to continue the culture.

[0222] After culturing for 72 hours after transfection, the cells were centrifuged at 3000 rpm for 5 minutes, and the supernatant (ie, the obtained CPV-2 recombinant pseudovirus fluid) was collected for testing the packaging efficiency of the CPV-2 recombinant pseudovirus carrying the EGFP fluorescent reporter gene.

[0223] Real-time fluorescence quantitative PCR was used to detect the titer of the recombinant pseudovirus in the supernatant: 437.5 μL of the collected supernatant was taken to extract viral DNA. Real-time fluorescence quantitative PCR was performed using quantitative primers CPV-EGFP F / CPV-EGFP R to detect that the DNA copy number of the CPV-2 recombinant pseudovirus in the cell supernatant after 72 hours reached 1×10 8.6 ( Figure 7 ).

[0224] (IV) Infectivity detection of CPV-2 recombinant pseudovirus carrying EGFP fluorescent reporter gene

[0225] F81 cells were evenly spread into a 24-well cell culture plate and cultured at 37°C with 5% CO2. When the cell density reached 70%, the cell supernatant was discarded, the cells were washed once with serum-free and anti-dual antibody-free culture medium, the collected CPV-2 recombinant pseudovirus fluid was added to the cell wells, and an equal volume of 5% FBS cell culture medium was added 4 hours after inoculation, and the cells were incubated for another 8 hours. The cell supernatant after incubation was discarded, the cells were washed once with serum-free and anti-dual antibody-free culture medium, and complete culture medium was added for further culture.

[0226] After F81 cells were infected with CPV-2 recombinant pseudovirus carrying EGFP fluorescent reporter gene, the expression of EGFP fluorescent reporter gene was observed under a fluorescence microscope at 24h, 48h and 72h. Green fluorescence was detected in cells infected with CPV-2 recombinant pseudovirus ( Figure 8 ), indicating that the packaged CPV-2 recombinant pseudovirus can successfully infect F81 cells and effectively express the foreign genes it carries.

[0227] Through the above examples, it can be seen that the present invention constructs a recombinant CPV-2 pseudovirus system for expressing exogenous genes by transforming the full-length infectious clone plasmid of CPV-2 into a replication-defective recombinant plasmid carrying exogenous genes, thereby overcoming the problem that the expression efficiency and assembly efficiency of the existing CPV-2 are limited when expressing exogenous genes. This not only provides a good research tool for the study of viral pathogenic mechanism, but also lays a theoretical foundation for the research and development of genetic engineering multi-unit vaccines and novel targeted drugs based on the CPV-2 pseudovirus system, and has a wide range of application prospects.

Claims

1. A recombinant canine parvovirus pseudovirus, characterized in that: It includes a recombinant plasmid and an auxiliary plasmid for expressing CPV-2 capsid protein; The recombinant plasmid includes an exogenous gene sequence and a core plasmid recombinant precursor connected to each other; the core plasmid recombinant precursor is a nucleotide sequence as shown in SEQ ID NO.1; The recombinant canine parvovirus pseudovirus is prepared according to the following method: the recombinant plasmid and the auxiliary plasmid for expressing CPV-2 capsid protein are transfected into cells, and the virus liquid is separated after continued cultivation to obtain the recombinant canine parvovirus pseudovirus.

2. The recombinant canine parvovirus pseudovirus according to claim 1, characterized in that: The exogenous gene sequence is the EGFP fluorescent reporter gene.

3. The recombinant canine parvovirus pseudovirus according to claim 1, characterized in that: The auxiliary plasmid for expressing CPV-2 capsid protein comprises a plasmid vector, a V1 segment, a V2 segment, a T2A segment and a V3 segment connected in series in sequence; Wherein, the V1 fragment is the nucleotide sequence shown in SEQ ID NO.2; The V2 fragment is a nucleotide sequence as shown in SEQ ID NO.3; The T2A is the nucleotide sequence shown in SEQ ID NO.4; The V3 fragment is the nucleotide sequence shown in SEQ ID NO.

5.

4. The recombinant canine parvovirus pseudovirus according to claim 3, characterized in that: The plasmid vector is selected from pCDNA3.

1.

5. The method for preparing the recombinant canine parvovirus pseudovirus according to claim 3 or 4, characterized in that: The steps include: Step 1, using CPV-2 genomic DNA as a template, amplifying the V1 segment, V2 segment and V3 segment, splicing the V1 segment and the V2 segment, and introducing T2A to connect the V2 segment and the V3 segment to obtain a segment VP2-T2A-VP1 containing an expression cassette transcription region; the VP2-T2A-VP1 comprises a V1 segment, a V2 segment, a T2A segment and a V3 segment connected in series in sequence; Step 2, connecting VP2-T2A-VP1 with the plasmid vector to obtain a helper plasmid for expressing CPV-2 capsid protein; Step 3, using the CPV-2 full-length infectious clone plasmid as a template, amplifying the core plasmid recombinant precursor, and connecting the core plasmid recombinant precursor with the exogenous gene sequence to obtain a recombinant plasmid; Step 4, transfecting the recombinant plasmid and the auxiliary plasmid for expressing CPV-2 capsid protein into cells, and separating the virus liquid after continuing to culture.

6. The preparation method according to claim 5, characterized in that: In step 1, the amplification primers include: The upstream primer used to amplify the V1 fragment has a nucleotide sequence as shown in SEQ ID NO.

7. The downstream primer used to amplify the V1 fragment has a nucleotide sequence as shown in SEQ ID NO.

8. The upstream primer used to amplify the V2 fragment has a nucleotide sequence as shown in SEQ ID NO.

9. The downstream primer used to amplify the V2 fragment has a nucleotide sequence as shown in SEQ ID NO.

10. The upstream primer used to amplify the V3 fragment has a nucleotide sequence as shown in SEQ ID NO.

11. The downstream primer used to amplify the V3 fragment has a nucleotide sequence as shown in SEQ ID NO.12; And / or, in step 2, VP2-T2A-VP1 and the plasmid vector are both ligated after being double-digested with BamH I / Xba I; And / or, in step 3, the amplification primers include: The upstream primer used to amplify the core plasmid recombinant precursor has a nucleotide sequence as shown in SEQ ID NO.

15. The downstream primer used to amplify the core plasmid recombinant precursor has a nucleotide sequence as shown in SEQ ID NO.16; The core plasmid recombinant precursor and the exogenous gene sequence are connected by ClonExpress II One Step Cloning Kit method; And / or, in step 4, the cells are F81 cells.

7. Use of the recombinant canine parvovirus pseudovirus according to any one of claims 1 to 4 for expressing foreign genes.